Back to search results

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Abroad (travel likely)RecruitingPHASE2

Conditions

Friedreich Ataxia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California Los Angeles, Los Angeles, California, United States

  • Fixel Institute for Neurological Disease, University of Florida Health, Gainesville, Florida, United States

  • Morsani Center for Advanced Health Care, University of South Florida Health, Tampa, Florida, United States

    Contact: Study coordinator (Kayla Zayas) · Kaylazayas@usf.edu · 813-974-5909
    Contact: Study coordinator (Lucretia Campbell) · lcampbel@usf.edu · 813-974-5909

  • University of Iowa, Iowa City, Iowa, United States

  • Uncommon Cures, Chevy Chase, Maryland, United States

    Contact: Study coordinator (Rachael Batabyal, MD) · Rbatabyal@uncommoncures.com · 240-858-4938
    Contact: Study coordinator (Tam Roshan Lal, MB, ChB) · troshanlal@uncommoncures.com · 240-858-4912

  • Clinilabs Drug Development, Corp., Eatontown, New Jersey, United States

  • Ohio State University United States, Columbus, Ohio, United States

  • Children's Hospital of the University of Pennsylvania (CHOP), Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (David Lynch, MD, PhD) · lynchd@pennmedicine.upenn.edu · 215-590-2242
    Contact: Study coordinator (McKenzie Wells, MS) · wellsm@chop.edu · 267-426-9608
Study leads

  • Larimar Therapeutics, Inc.

    Study Chair

    Larimar Therapeutics, Inc.

View source on ClinicalTrials.gov(opens in a new tab)